Skip to main content
SpringerLink
Log in

ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve “Precision Onco-Surgery” in Resectable Colorectal Liver Metastases

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. Oct 1 2019;25(19):5843–5851.

    Article  CAS  Google Scholar 

  2. Kobayashi S, Takahashi S, Takahashi N, et al. Survival outcomes of resected BRAF V600E mutant colorectal liver metastases: a multicenter retrospective cohort study in Japan. Ann Surg Oncol. Jul 13 2020.

  3. Nakamura Y, Taniguchi H, Ikeda M, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. Oct 5 2020.

  4. Kobayashi S, Nakamura Y, Taniguchi H, et al. Impact of preoperative circulating tumor DNA status on survival outcomes after hepatectomy for resectable colorectal liver metastases. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09449-8.

    Article  PubMed  Google Scholar 

  5. Kobayashi S. Multi-center clinical trial for personalized perioperative chemotherapy based on genetic alteration status for resectable oligometastases from colorectal cancer. 2020; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000048502. Accessed 19th November, 2020.

Download references

Acknowledgements

This study received financial support from the National Cancer Center Research Development Fund (Research Number: 30-A-8, Principal investigator: Shinichiro Takahashi).

Author information

Author notes

  1. Shin Kobayashi and Yoshiaki Nakamura have contributed equally to this manuscript.

Authors and Affiliations

  1. Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan

    Shin Kobayashi MD, PhD & Shinichiro Takahashi MD, PhD

  2. Department of Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 2770882, Japan

    Yoshiaki Nakamura MD, PhD, Hiroya Taniguchi MD, PhD & Takayuki Yoshino MD, PhD

Authors
  1. Shin Kobayashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiaki Nakamura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinichiro Takahashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroya Taniguchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takayuki Yoshino MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takayuki Yoshino MD, PhD.

Ethics declarations

Disclosure

The authors disclose potential conflicts of interest as follows: Yoshiaki Nakamura, research funding from Taiho pharmaceutical company and Genomedia Inc.; Hiroya Taniguchi, honoraria from Takeda, Chugai, and Taiho pharmaceutical companies. Research funding from Takeda, Daiichi-Sankyo, Taiho, Ono Pharmaceutical companies; Takayuki Yoshino, research funding from Novartis Pharma, MSD, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Sanofi, Daiichi Sankyo, Parexel International, Ono Pharmaceutical, and GlaxoSmithKline companies.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, S., Nakamura, Y., Takahashi, S. et al. ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve “Precision Onco-Surgery” in Resectable Colorectal Liver Metastases. Ann Surg Oncol 28, 4756–4757 (2021). https://doi.org/10.1245/s10434-020-09456-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-09456-9

Search

Navigation